The Study
1411-P: Relative and Absolute Risk Reduction for MACE in Cardiovascular Outcomes Trials with GLP-1 Receptor Agonists in Type 2 Diabetes Patients with and without ASCVD at Baseline
This study looked at many big experiments where people were randomly given either a new medicine or a sugar pill. It found that the medicine helps reduce heart problems, especially in people who already had heart disease. But it doesn't prove why it works—just that it does.
Analysis score
Maximum 100 for a systematic review with meta-analysis.
Where the score came from
These drugs lower heart attack and stroke risk in diabetics, but how much they help depends on whether you already have heart disease.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 560 / 100
Quality score
The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.
Key takeaways
Summary
Based on the study abstract and findings.
- 1For someone with heart disease, treating 47 people prevents one major event — that’s a strong benefit.
- 2For someone without heart disease, you’d need to treat 109 people to prevent one event — much less efficient.
- 3In diabetics with existing heart disease: 2.12% fewer had heart events over 3 years (NNT=47).
- 4In diabetics without heart disease: 0.92% fewer had heart events (NNT=109).
- 5The percentage reduction was similar (17% vs.
- 611%).
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Diabetes
Year
2026
Authors
Michael A. Nauck, B. Stratmann, S. Reger-Tan, Y. Lee-Barkey
Related Content
Claims (6)
GLP-1 drugs have different effects on heart health in different people.
In patients with type 2 diabetes and established atherosclerotic cardiovascular disease, GLP-1 receptor agonists lower the occurrence of major adverse cardiovascular events by 17% compared to no such treatment, with an absolute reduction of 2.12% over three years.
In people with type 2 diabetes but no prior heart disease, GLP-1 receptor agonists lower the chance of serious heart problems such as heart attack, stroke, or death by 11% over three years compared to no such treatment.
In people with type 2 diabetes, GLP-1 receptor agonists reduce the risk of major heart events by a similar proportion whether or not they already have artery disease.
In people with type 2 diabetes and existing heart disease, GLP-1 receptor agonists lower the chance of serious heart events by 2.12% over three years. In people with type 2 diabetes but no prior heart disease, the reduction is 0.92% over the same period.
Among type 2 diabetes patients, GLP-1 receptor agonists prevent one major cardiovascular event in every 47 patients with existing heart disease over three years, and in every 109 patients without existing heart disease.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.